ALKS earnings call for the period ending December 31, 2019.
News & Analysis: Alkermes
A patent case win for its partner Biogen will give the duo time to convince multiple sclerosis patients to switch from Tecfidera to Vumerity.
ALKS earnings call for the period ending September 30, 2019.
The biotech had $4.3 billion in sales at risk.
A slow launch has investors worried.
ALKS earnings call for the period ending June 30, 2019.
Generic competition is dragging down revenue this year, but it has FDA approvals in the wings.
ALKS earnings call for the period ending March 31, 2019.
Sales of the drugmaker's schizophrenia drug Aristada disappointed investors.
It took a few drugs to get there.